Recurrent Respiratory Papillomatosis
Conditions
Interventions
Test group:Bevacizumab injection (specification: 100 mg/4 mL) was administered intralesionally to the laryngeal lesions following microscopic laryngeal surgery under general anesthesia. Approximately
Sponsors
The Affiliated BenQ Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Ages 1-75; 2.Histopathology confirmed recurrent respiratory papilloma; 3.Lesions primarily confined to the larynx; 4.Patients selected for treatment with intralesional bevacizumab injection; 5.Willingness to provide signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2.Bleeding tendency or active hemorrhage prior to treatment; 3.Bevacizumab allergy; 4.Have other throat diseases that affect treatment or follow-up; 5.Severe cardiac, liver and renal insufficiency or other surgical contraindications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to recurrence; | — |
Secondary
| Measure | Time frame |
|---|---|
| The voice disturbance scale 10 was evaluated before treatment and during follow-up; Derkay score at mean recurrence during follow-up;Safety of Bevacizumab therapy; | — |
Countries
China
Contacts
Public ContactYuanyuan Lu
The Affiliated BenQ Hospital of Nanjing Medical University
Outcome results
None listed